Pfizer’s Core Drugs Offset COVID Revenue Drop, Lifts 2025 Profit Outlook Despite Tariffs

All NewsNovember 4, 2025

Pfizer beat Q3 estimates with 87 cents EPS, raised 2025 profit guidance, as Eliquis and Vyndaqel growth offset declining COVID product sales.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent